

Peptide Phage Display

Fumiaki UCHIYAMA,* Saeko MOURI, Tomomi CHIHARA

Department of Molecular Biosciences, Institute of Preventive and Medicinal Dietetics, Nakamura-Gakuen University, 5-7-1 Befu, Jounan-Ku, Fukuoka, 814-0198, Japan

*Corresponding author. E-mail: uchiya-f@nakamura-u.ac.jp

Phone: +81-(0)92-851-2598 fax: +81-(0)92-841-7762

[**Key words:** phage display; disulfide bridge; constraint; conformational diversity; random peptides]

Abstract

Phage display is emerging as a promising strategy for the discovery of peptide ligands that are used for analytical tools, drug discovery, and target validations. Phage display technology can produce a huge number of peptides and generate novel peptide ligands. Phage display technology has successfully managed to create some peptide ligand. The structural analysis of ligands shows that the conformational design of peptides in library is important for structural relationship among peptides on phage, synthetic peptides and non-peptidic compounds as well as for selecting high-affinity ligands that bind to every target from a phage peptide library. Key issues concern constraints on the conformation of peptides on the phage and the development of chemically synthesized peptides derived from peptides on phage. This review discusses studies related to the conformation of peptides selected from phage display peptide libraries in addition to the conversion from peptides to non-peptides.

TECHNOLOGICAL OVERVIEW OF PHAGE DISPLAY

Fusion proteins can often retain the biological function of original proteins. The minor coat protein of filamentous bacteriophage can tolerate the fusion of peptides for display on the phage¹. A vast number of peptides can be produced using one phage per peptide corresponding to foreign DNA inserts. The particles of fusion phages have been treated as peptide-immobilized beads in affinity purification and as organisms in amplification^{2,3}. Therefore, phage display is a very cost-effective and time-saving technology. Filamentous phages have been extensively used to display random peptides as fusions of the minor coat protein pIII^{2,3}, the major coat protein pVIII⁴, or the minor coat protein pVI⁵. There are two basic display formats that can be selected from phage-display vectors. Polyvalent display generates every copy of the capsid protein displaying the fusion using a viral vector^{2,3}. Monovalent display generates a mosaic of the wild-type and recombinant capsid proteins using helper phage⁶. Phage-display

vectors are critical in the construction of phage libraries because vectors determine the expression and incorporation of inserted peptides into virions. These display formats are mainly used for pVIII as well as pIII fusions. Other phages, such as bacteriophage λ ⁷ and bacteriophage T4⁸, have been used in similar display systems. Peptides have also been displayed on the outer membrane of bacteria⁹ and yeast¹⁰⁻¹² using several outer membrane proteins. Each display system has advantages in the binding capacity to targets as well as the production of peptides. It is unknown how the surface accessibility of organism particles globally influences the interaction to target proteins.

Since Scott and Smith reported a peptide display library on filamentous bacteriophage², phage display has been successfully innovated in vector design, screening methods, and applications. There is particular interest in investigating vector design because fusion proteins cause biological bias in the process of translocation, assembly, and folding. There is competition between the technologies imposed on the efficient expression of exogenous peptides on phage and the biological exclusion

of exogenous peptides by phage as well as host cells¹³. Phage display technology has been developed for application to protein-protein interactions in various fields. In the discovery of peptide ligands, there are many recent reports of applications such as the identification of epitopes or vaccines, enzyme substrates¹⁴⁻¹⁸, DNA-binding peptides^{19,20}, enzyme inhibitors²¹⁻²⁹, protein binding peptides³⁰⁻⁴², receptors⁴³⁻⁵¹, dimerization peptide units⁵², tissue-specific homing peptides⁵³⁻⁵⁵, and cell- or organism-binding peptides⁵⁶⁻⁶³. There are also many general reviews on phage display⁶⁴ covering topics such as random peptide libraries^{65, 66}, constrained peptide libraries^{67, 68}, phage biology¹³ and applications⁶⁹⁻⁷¹. Moreover, phage display technology extends to the synthesis of artificial proteins with random sequences⁷². The selection of novel peptide ligands from random peptide libraries is usually performed by panning². Panning processes have been developed to solve the problems caused by immobilized targets⁷³. Panning generates peptides with consensus sequences. Peptides are chemically synthesized on the basis of the consensus sequences and are evaluated by bioassay and structural analysis.

Although peptide libraries are ideal for displaying equal frequencies of amino acids in random sequence, it is difficult to realize frequency control using the present technology. The factors underlying this issue have been discussed in detail¹³. The random peptide on a phage is expressed as a fusion protein in host cells and the biological and chemical properties of fusion proteins is a key issue in display technology.

MOTIFS IN PEPTIDE LIBRARIES

The first phage library was constructed with the design of linear random peptides by fusion to the N terminus of pIII of filamentous bacteriophage^{2, 3}. Screening from the phage display peptide library was performed to determine the epitope of antibodies by repetitive affinity selection called panning. The peptides binding to an antibody were selected from 10 million of hexapeptides using several cycles of panning. The two monoclonal antibodies, Mab A2 and M33, which are specific for the hexapeptide DFLEKI of myohemerythrin, were used for the screening of the library. The peptides bound to these Mabs had the consensus sequence DFLX₃². Independently, the random hexapeptides on the N terminus of pIII were screened for the

3-E7 monoclonal antibody, which is specific for the N terminus of β -endorphin YGGF³. The consensus sequence was identified as YGX₄. It is critical that the YGX₄ sequence contains Y-G on the N terminus. These results show that the phage libraries with linear random peptides can be applied to identify epitopes consisting of a continuous primary sequence. The subsequent identifications of epitopes have been successfully applied to epitope mapping⁷⁴⁻⁷⁸ and to mimicking the carbohydrate structures of bacteria, cancer cells, or viruses⁷⁹⁻⁸¹. Linear peptide libraries, which are constructed by the fusion of peptides to the N terminus of pVIII as well as pIII in filamentous phage, are useful to identify epitopes for monoclonal antibodies. The chain length of random sequences is the main consideration in the design of linear peptides. The selection of epitopes on the human tumor suppressor protein p53 revealed different sequences depending on the chain length of random peptides⁸². Monoclonal antibody PAb421 against p53 recognizes a ten-amino acid synthetic peptide, KKGQSTRHK, equivalent to the C-terminal region of p53. The epitope of PAb421 is proposed to involve residues widely spaced in the primary sequence, constituting a discontinuous epitope. Three types of phage library, which consisted of 6-mer, 12-mer, or 20-mer random peptides fused to the N terminus of pIII, were used for the reaction of the monoclonal antibody PAb421. The KXXXSTSXHXK motif with p53-homologous sequences was isolated from the 12-mer and 20-mer libraries, and the selection from the 6-mer library led to the isolation of sequences with the R/KXXXK motif with no discernible homology to p53. The selection using monoclonal antibody PAb240 gave the RHS motif common to the three libraries. This work demonstrated the importance of the chain length of random peptides for the identification of discontinuous epitopes. Moreover, peptide libraries have to be designed based on the characteristics of the target and the choice of peptide such as epitope or mimotope.

Some linear peptides can form structural scaffolds based on both amino acid sequence and chain length of the peptide. A 15-mer library was constructed by the fusion of peptides to the N terminus of pIII on filamentous phage and was screened to identify the peptides that bind to streptavidin. The selected peptides had the consensus sequence HPQ and some of them were cyclic peptides³. The HPQ motif was subsequently also identified as a ligand of streptavidin^{83, 84}. As the

proline residue in peptides is restricted by the N-C α torsion angle ϕ , motifs containing proline stabilize β -turn conformations. Disulfide bridges also constrain the conformation of peptides. Therefore, the consensus sequence HPQ on phage is very likely to generate peptides with β -turn conformations. In fact, crystal structures of streptavidin-bound linear and cyclic peptide ligands containing the HPQ sequence, FSHPQNT⁸⁵, cyclo-Ac-[CHPQGPPC]-NH₂ and cyclo-Ac-[CHPQFC]-NH₂⁸⁶ showed that the peptides bound in a β -turn conformation. The sequence containing HPQ is a common motif for binding to streptavidin. These studies illustrated the importance of turn conformation and led to the construction of peptide libraries containing a cystine bridge in phage display.

Many motifs are found in the sequences of natural proteins. As shown in Table 1, motifs have also been identified by selection from phage libraries. The consensus sequence is often developed into a peptide motif. To identify higher affinity ligands from peptide libraries, the motif of GP or DEY were applied to construct the library with a di- or tri-peptide in random sequence^{41,44}.

It is dependent on peptide sequences whether motifs play a role in either the structural scaffold or surface contact with the target. Currently, this issue is being clarified by structural analysis using co-crystallization or NMR spectroscopy. A library with a general motif X₄CX₂GPX₄CX₄ led to the identification of a peptide with the sequence of CRAGPLQWLCEKYFG that bound to the insulin-like growth factor binding protein-1 (IGFBP-1). The synthetic peptide CRAGPLQWLCEKYFG was analyzed by NMR spectroscopy and adopted a turn-helix structure. The hydrophobic residues (two Leu, Trp, Tyr, Phe) provided direct contact to IGFBP-1 as well as stabilization of the peptide conformation. The structural scaffold attributed a turn structure to the Cys, Gly, and Pro residues, and a helix to the sequence of KYFG⁸⁷. These results showed that the sequence motif might be essential for both the structural scaffold and direct contact with the target. As the peptides by displayed phage are small in size, some amino acid residues play a dual role in structural stabilization and direct contact with targets.

CYSTINE BRIDGE SCAFFOLD IN PEPTIDE LIBRARIES

TABLE 1 Targets and motifs of amino acid sequences selected from phage libraries

Target	Motif	Ref.
EPOR	GGTYSCHFGPLTWVCKPQGG	49
	DREGCRRGWVQCKAWFN	44
IGFBP-1	CRAGPLQWLCEKYFG	41
Complement C3	ICVVQDWGHHRCT	29
Calmodulin	SCLRWGWKWSNCGS	32
IgE receptor	XXCPXXCYX	45
Syntrophin PDZ domain	XXETCXAGXXC	42
Angiotensin-converting enzyme 2	CXPXRXXPWXXC	27
Streptavidin	HPG	3
Androgen receptor coregulators	FXXL(F/Y)	111
Alpha M beta 2 integrin	(D/E)(D/E)(G/L)W	112
Urokinase-type plasminogen activator	BXXSSXXB	113
V-type H ⁺ -ATPase	WLELRP	114
Antibodies from prostate cancer patients	NX(S/T)DK(S/T)	115
P-selectin	EWVDV	116
Peripheral-type benzodiazepine receptor	STXXXXP	117
FGF receptor	MXXP	118
Leukocyte-specific beta(2) integrins	LLG	119
X-inhibitor of apoptosis protein	C(D/E/P)(W/F/Y)-acid/basic-XC	120

B represents a basic amino acid and X represents any amino acid

It is a design goal that the conformation of peptide is such that a bioactive peptide is generated. Moreover, the characteristics of peptides are used for the development of non-peptide structures to create drug candidates. The conformation of peptides is basically determined by amino acid sequences. In linear peptide libraries, the sequences are random, but a longer peptide chain is required to generate a rigid conformation. A library containing 8-mer random peptides has a theoretical diversity of 2.6×10^{10} members. To construct this library, transformants with 1.1×10^{12} members is required in genetic diversity. This is generally an experimental limitation in the construction of a complete library. Even when a library of longer peptides is constructed, both the structural analysis and the development of non-peptide structures are more complex in correlation with the peptide chain length. Therefore, it is a practical approach that a peptide library has a structural scaffold. Ligands interacting with proteins biologically adopt a α -helix, β -strand, or loop structure. The α -helix and β -strand structures stabilize longer peptide chains. The α -helix structure is essential to the

biological functions of some peptide hormones^{88,89}, which may be mimicked in the screening of peptide libraries with an alpha-helically homogenous conformation^{90,91}. Loop structures play an important role in the molecular recognition of protein-protein or protein-peptide interactions, and they may be a scaffold candidate for peptide libraries. Many libraries have been developed to introduce a constraint into peptides^{67,68}. Random peptides sandwiched by a pair of cysteine residues are used to cause constraints. Employing a constraint caused by a cystine bridge resulted in the discovery of a ligand for the erythropoietin receptor (EPOR)⁴⁹. A peptide bound to EPOR was identified by screening from a phage library of random octapeptides flanked by cysteines. By using synthetic peptides, it was shown that peptides with a consensus sequence YXCX₂GPXTWXCXP had an agonistic activity against EPOR. One of the peptides, GGTYSCHFGPLTWVCKPQGG, was structurally analyzed with co-crystals⁵⁰. The crystal structure of a complex of this peptide with an extracellular domain of EPOR generated important information for peptide design. The sequence of GPLTW is involved in both peptide-receptor and peptide-peptide interactions. The sequence of GPLT revealed a type I beta structure turn. This result agrees with the fact that both proline and glycine residues preferentially generate the turn conformation according to empirical prediction. These results indicated that the turn structure might be effective for the formation of a cystine bridge as well as bioactivity. In another report of EPOR agonist peptides, a consensus sequence of CX₂GWVGXCX₂W was isolated from 38-mer random peptides of a phage library⁴⁴. This sequence also contains glycine residues and a tryptophan residue in the cystine bridge. A library with the sequence motif X₄CX₂GP₂X₄CX₄ led to the identification of a peptide with the sequence of CRAGPLQWLCEKYFG that bound to IGFBP-I⁴¹. Although this motif is common to EPOR agonist peptides, the tertiary structures of these peptides in solution are very different⁸⁷. The turn structure with a cystine bridge has various conformations in common motifs and is still flexible so as to be under the influence of constituent amino acid residues. The motifs identified using phage display are shown in Table 1. Interestingly, the sequences of ligands selected from phage libraries with cystine bridges have a high frequency of proline, glycine, or tryptophan residues as the preferential

constituent amino acid residues in a random sequence. The abundance of proline residues may result from the predominant sequence bias due to the formation of a cystine bridge⁹².

As shown in the structure of EPOR agonist peptides, most peptides from phage libraries do not have clearly distinguished binding sites from structural scaffold residues. The distinction can be made by designing non-peptides derived from peptides. Peptide hormones are unsuitable for drugs due to their poor oral bioavailability and less stability in circulation. On the other hand, many challenges have been encountered in the synthesis of non-peptides derived from peptides as a rational approach. Somatostatin is a well-known example of the development of non-peptide structures substituting for the peptide backbone. Somatostatin is a disulfide-linked cyclic tetradecapeptide, AGCKNFFWKTFTSC⁹³ and regulates the release of hormone such as growth hormone, glucagon, insulin, and gastrin through various somatostatin receptor subtypes⁹⁴. The sequence of FWKT in somatostatin is essential for activity and the other amino acid residues constitute the peptide backbone. The peptide backbone was substituted with beta-D-glucose⁹⁵, mannitol⁹⁶, and biphenyl scaffolds⁹⁷. Moreover, totally non-peptide somatostatin agonists were discovered^{98,99}. Therefore, the distinction of binding sites from the peptide backbone may be important for the design of peptide libraries to address pharmaceutical interests. The backbone of somatostatin is a design candidate for constructing peptide phage libraries because of the abundant knowledge regarding its medicinal chemistry as well as structural analysis.

In the design of peptide conformation, disulfide-linked cyclic peptides in phage libraries are predominantly considered. There are many naturally occurring peptides containing cystine bridges. Peptide hormones are often synthesized as large proprotein precursors. After processing, mature bioactive peptides are stored in secretory granules that are released by specific stimulations. Therefore, the backbone of mature peptide hormones seems to be formed in the proprotein. The partial sequences of peptide hormones are shown in Table 2. Surprisingly, there are no proline residues in the sequence sandwiched by cystine bridges in peptide hormones. The numbers of turns in peptide hormones may increase due to the global interaction of the peptide backbones. On the other hand, the over-abundance of

TABLE 2 Naturally occurring peptides and their sequences in cystine bridges

Peptide	Sequence in cystine bridges
Adrenomedullin	CRFGTC
Atrial natriuretic factor	CFGGRMDRIGAQSGLGC
Brain natriuretic peptide	CFGKMDRISSSSLGC
Calcitonins	CGNLSTC
CGRP	CDTATC
Cortistatin-17	CRNFFWKTFSSC
Endothelin-1	CSCSSLMDKECVYFC
Endothelin-2	CSCSSWLDKECVYFC
Endothelin-3	CTCFYTKDKECVYYC
Orexin A	CCRQKTCSC
Oxytocin	CYIQNC
Somatostatin	CKNFFWKTFSC

CGRP, Calcitonin gene-related peptide

proline residues in a cyclic dodecapeptide library was reported in the analysis of amino acid residue occurrence patterns⁹². The proline residue has a high propensity to adopt β -turns because of the restriction by the N-C α torsion angle. In fact, proline residues have been used in synthetic peptides to stabilize β -turn conformations¹⁰⁰. Therefore, the sequences containing proline residues generate β -turns by themselves, which is dependent on local conformational effects, rather than by the peptide backbone constraints. All random peptides have been displayed on phage by fusion to the terminal end of phage proteins, pIII or pVIII, although there are many types of phage display systems⁶⁴. The conformation of random peptides in phage display is little affected by parent proteins. This agrees with the fact that an abundance of proline residues was observed in a cyclic dodecapeptide library⁹². This also gives the advantage of simply designing synthetic peptides derived from peptides on phage. Phage peptide display should facilitate the synthesis of peptides. The bioactivity of cyclic peptides on phage is often identical to that of synthetic peptides that are designed based on the primary sequence. On the contrary, the search for bioactive peptide fragments in a protein is sometimes successful in the preparation of peptide fragments from the primary sequence, but difficult in relation to the conformation of bioactive regions. In this way, the constraint of disulfide-linked cyclic peptides in phage libraries is different from that of naturally occurring small peptides with a

cystine bridge from the viewpoint of cyclic strain energy.

The design of cyclic random peptides for display on phage may be regarded as the optimization of the loop length. A strong inverse correlation was observed between loop length and stability in a four-helix-bundle protein¹⁰¹. Reducing the loop length led to the minimization of atrial natriuretic peptide (ANP) using phage display¹⁰². The natriuretic peptide receptor-A-binding determinants consist of 7 amino acid residues, Phe⁸, Met¹², Asp¹³, Arg¹⁴, Ile¹⁵, Leu²¹, and Arg²⁷ in the sequence of ANP, shown in Table 2 and reoptimized as a 15-mer cyclic peptide, MCHFGGRMDRISCYR. The sequences of both MCH and SCYR make the conformation of the continuous sequence FGGRMDRI identical to that of ANP. The conformations of the sequence FGGRMDRI may be almost identical between the 15-mer cyclic peptide and ANP. In this way, the sequence between the cysteine residues that form the cystine bridge may strongly affect the structural conformation in peptide libraries. The sequences that are 5' and 3' of the cystine residues forming the cystine bridge may contribute to the conformation of inner random peptides, contact surface to target, or phage assembly. Libraries displaying peptides with various loops were constructed and used for the successful selection of targets of interest. In the present technology, the designs for cyclic random peptides are illustrated as the sequence X_nCX_mCX_n in fusions of the terminal ends of phage proteins¹⁰³. However, the disulfide-linked peptide library exhibits conformational as well as amino acid sequence diversities even in identical libraries.

CONFORMATIONALLY CONSTRAINED LIBRARIES USING THE LOOP STRUCTURE OF PROTEIN SCAFFOLD

The low flexibility of peptide molecules can reduce the entropic costs for binding to targets. The conformation of the loop structure is rigid in the tertiary structure of proteins. Phage libraries were constructed by substituting random peptides for the amino acid residues in the loop structure of proteins. Tendamistat is an inhibitor of α -amylase, and a 74-amino acid molecule comprised of two three-strand β sheets¹⁰⁴. The loop structure of tendamistat has also been applied in the peptide chemistry of a combinatorial library¹⁰⁵. Random

hexapeptides substituted for the loop extend between amino acids 60 to 65 of tendamistat were recognized by mAbA8, a monoclonal antibody against endothelin, to reveal the most frequent sequence of FNVTYA. On the other hand, the consensus sequence LEPW was selected by the mAbA8 antibody from random hexapeptides fused to pIII, but not from the tendamistat random peptide library¹⁰⁶. The affinity of tendamistat phage containing FNVTYA to mAbA8 was a little higher than that of the phage displayed CWLEPWLC flanked by pIII. The peptides containing LEPW were selected from the libraries with or without a cystine bridge. There is no homology among the sequences of FNVTYA, WLEPW, and endothelin. This means that the feature of peptide may be important for mimotopes rather than primary sequences. These results show that the constraint may not be imposed by a cystine bridge in N-terminal linked libraries, or may be largely affected by the constituent amino acid residues in N-terminal fusions. On the contrary, the constraint of peptides in the loop structures of proteins is dependent on the multiplicity of interaction in tertiary structures, and is relatively constant in a library. In another study, the tendamistat peptide library containing a fixed RGD sequence was used for the specific selection of ligands of the integrin family¹⁰⁷. That study shows that tendamistat fusions may control the conformations of the RGD motif in minute detail similar natural ligands of integrin.

IN THE FUTURE

Since phage peptide libraries was first reported in 1990², phage display has been successfully used in various research fields. There have been many technical innovations in phage display systems particularly in the past decade⁶⁴. Moreover, phage display technology has improved the binding properties of peptides to target proteins by designing the conformation of peptides. Structural stability plays a role in the determination of the local conformation of peptides. As a result, the consensus sequences are selected from linear or cyclic random peptide libraries. The random peptide X_nCX_nP X_nCX_n may be an excellent design for phage display as far as using N- or C-terminal fusions is concerned because of the successful selection of ligands to EPO R⁵⁰, IgE receptor⁴⁵, or IGFBP-1¹¹. If the X_n residues are sufficiently long to interact with each other, the

inclusion of proline residues will not be necessary. The reason for this is because the interaction of the X_n residues causes the peptide fragment within a cystine bridge to form a β -turn. The global conformation of tendamistat in a phage display peptide library imposes a rigid conformation on random peptides as in peptide hormones¹⁰⁶. Therefore, the conformational rigidity of random peptides in a tendamistat library is uniformly generated independent of the random peptide sequence. Other protein scaffolds or novel fusions are expected to generate other rigid conformations in phage display systems.

As a promising approach for drug discovery, phage display technology will be implicated in the discovery of non-peptidic compounds through the structural requirements of peptides selected from phage libraries, as outlined in Fig. 1. We constructed a peptide library by insertion of peptides into pIII (Uchiyama *et al.*, in preparation). The design of peptides on phage is a model based on the structure of somatostatin, and consists of the stem and loop structure in pIII. The stem region




FIG. 1 Retro-design of the scaffold of random peptides. The rectangles with solid lines show the backbones which can convert from peptide regions inserted into pIII to non-peptide regions. The rectangles with dotted lines show the target binding sites which can convert from peptides to non-peptides. The circles with X or Y consist of amino acid residues and Z shows the functional group. The dotted lines between Y letters show the interaction between amino acid residues. The hexagons show non-peptidic and cyclic compounds. Conventional conversions are indicated by open arrows and the virtual conversions using the retro-design of the scaffold are indicated by closed arrows.

is a scaffold and is composed of six amino acid residues from Y1 to Y6. The binding region, from residues X1 to X4, makes direct contact with targets. The two regions in small peptides can be functionally distinguished. A somatostatin scaffold was used for the discovery of an antagonist to the tachykinin receptor 1¹⁰⁸, although there is no sequence homology between the tachykinin receptor 1 and somatostatin receptors. The role of a disulfide bond is not constrain the peptides, but to stabilize the interaction of the stem structure, because the introduction of a disulfide bridge was not as effective as the generation of a conformational constraint. The stem structure of peptides on phage can be converted to non-peptide scaffolds⁹⁵⁻⁹⁸. The binding region of peptides can be substituted with non-peptides to generate non-peptidic compounds⁹⁹. These conversions are described in the foregoing example of somatostatin. It may be more efficient in drug discovery that as a retro-design, the scaffold of peptides on phage is designed in consideration of non-peptidic compounds. As a retro-design shown in Fig. 1, the conformational design of random peptides in phage libraries was performed on the basis of a non-peptidic scaffold.

The bioactivity of synthetic peptides based on the primary sequence is almost the same as that of peptides on phage in N- or C-terminal fusion libraries^{41, 45, 50}. This is because N- or C-terminal fusion peptides are structurally independent of the parent protein. In the synthesis of peptides selected from the tendamistat library, the scaffold which is structurally equivalent to anti-parallel β strands of tendamistat should be coupled to both ends of the peptides. The tendamistat scaffold will be more useful in phage display for medicinal chemistry if a non-peptidic scaffold for the tendamistat library can be found.

In protease inhibitors, the protein-protein binding interfaces have been recognized to involve 10 to 15 residues of ligands by crystallographic studies, and the protein-protein complex is attributed to the rigid preformed binding loops¹⁰⁹. A small subset of residues in a functional epitope was reported to dominate hot spots of the binding energy in protein-protein interfaces¹¹⁰. Designing the scaffolds of peptides for phage-display peptide libraries will become increasingly important for the analysis of protein interaction and enable to the discovery of mimics of the smaller functional epitopes. Phage display technologies are becoming more powerful in combination

with other technologies. To address a rational approach for drug discovery, peptide designs are being performed under the integration of phage display technology, peptide chemistry, structural analysis, and medicinal chemistry.

REFERENCES

1. Parmley, S. F. and Smith, G. P.: Antibody-selectable filamentous fd phage vectors: affinity purification of target genes. *Gene*, 73, 305-318 (1988).
2. Scott, J. K. and Smith, G. P.: Searching for peptide ligands with an epitope library. *Science*, 249, 386-390 (1990).
3. Devlin, J. J., Panganiban, L. C., and Devlin, P. E.: Random peptide libraries: a source of specific protein binding molecules. *Science*, 249, 404-406 (1990).
4. Felici, F., Castagnoli, L., Musacchio, A., Jappelli, R., and Cesareni, G.: Selection of antibody ligands from a large library of oligopeptides expressed on a multivalent exposition vector. *J. Mol. Biol.*, 222, 301-310 (1991).
5. Jespers, L. S., Messens, J. H., De Keyser, A., Eeckhout, D., Van den Brande, I., Gansemans, Y. G., Lauwereys, M. J., Vlasuk, G. P., and Stanssens, P. E.: Surface expression and ligand-based selection of cDNAs fused to filamentous phage gene VI. *Biotechnology (N Y)*, 13, 378-382 (1995).
6. Bass, S., Greene, R., and Wells, J. A.: Hormone phage: an enrichment method for variant proteins with altered binding properties. *Proteins*, 8, 309-314 (1990).
7. Sternberg, N. and Hoess, R. H.: Display of peptide and proteins on the surface of bacteriophage lambda. *Proc. Natl. Acad. Sci. USA*, 92, 1609-1613 (1995).
8. Malys, N., Chang, D. Y., Baumann, R. G., Xie, D., and Black, L. W.: A bipartite bacteriophage T4 SOC and HOC randomized peptide display library: detection and analysis of phage T4 terminase (gp17) and late sigma factor (gp55) interaction. *J. Mol. Biol.*, 319, 289-304 (2002).
9. Georgiou, G., Stathopoulos, C., Daugherty, P. S., Nayak, A. R., Iverson, B. L., and Curtiss, R., 3rd: Display of heterologous proteins on the surface of microorganisms: from the screening of combinatorial libraries to live recombinant vaccines. *Nat. Biotechnol.*, 15, 29-34 (1997).
10. Zou, W., Ueda, M., Yamanaka, H., and Tanaka, A.: Construction of a combinatorial protein library displayed on yeast cell surface using DNA random priming method. *J. Biosci. Bioeng.*, 92, 393-396 (2001).
11. Ueda, M. and Tanaka, A.: Cell surface engineering of yeast: construction of arming yeast with biocatalyst. *J. Biosci. Bioeng.*, 90, 125-136 (2000).
12. Ueda, M. and Tanaka, A.: Genetic immobilization of proteins on the yeast cell surface. *Biotechnol. Adv.*, 18, 121-140 (2000).
13. Wilson, D. R. and Finlay, B. B.: Phage display: application, innovations, and issues in phage and host biology. *Can. J. Microbiol.* 44, 313-329 (1998).

14. O'Boyle, D. R., 2nd, Pokornowski, K. A., McCann, P. J., 3rd, and Weinheimer, S. P.: Identification of a novel peptide substrate of HSV-1 protease using substrate phage display. *Virology*, 236, 338-347 (1997).
15. Yoshida, H., Yagi, Y., Ikebukuro, K., and Sode, K.: Improved substrate specificity of water-soluble pyrroloquinoline quinone glucose dehydrogenase by a peptide ligand. *Biotechnol. Lett.*, 25, 301-305 (2003).
16. Pan, W., Arnone, M., Kendall, M., Grafstrom, R. H., Seitz, S. P., Wasserman, Z. R., and Albright, C. F.: Identification of peptide substrates for human MMP-11 (stromelysin-3) using phage display. *J. Biol. Chem.*, 278, 27820-27827 (2003).
17. Dall'Acqua, W., Halin, C., Rodrigues, M. L., and Carter, P.: Elastase substrate specificity tailored through substrate-assisted catalysis and phage display. *Protein Eng.*, 12, 981-987 (1999).
18. Cloutier, S. M., Chagas, J. R., Mach, J. P., Gygi, C. M., Leisinger, H.J., and Deperthes, D.: Substrate specificity of human kallikrein 2 (hK2) as determined by phage display technology. *Eur. J. Biochem.*, 269, 2747-2754 (2002).
19. Cheng, X., Kay, B. K., and Juliano, R. L.: Identification of a biologically significant DNA-binding peptide motif by use of a random phage display library. *Gene*, 171, 1-8 (1996).
20. Secco, P., Cotella, D., and Santoro, C.: Selection of peptides with affinity for the N-terminal domain of GATA-1: identification of a potential interacting protein. *Biochem. Biophys. Res. Commun.*, 305, 1061-1066 (2003).
21. Houimel, M., Mach, J. P., Corthesy-Theulaz, I., Corthesy, B., and Fisch, I.: New inhibitors of *Helicobacter pylori* urease holoenzyme selected from phage-displayed peptide libraries. *Eur. J. Biochem.*, 262, 774-780 (1999).
22. Mukhija, S. and Erni, B.: Phage display selection of peptides against enzyme I of the phosphoenolpyruvate-sugar phosphotransferase system (PTS). *Mol. Microbiol.*, 25, 1159-1166 (1997).
23. Karasseva, N. G., Glinsky, V. V., Chen, N. X., Komatireddy, R., and Quinn, T. P.: Identification and characterization of peptides that bind human ErbB-2 selected from a bacteriophage display library. *J. Protein Chem.*, 21, 287-296 (2002).
24. Koiwa, H., D'Urzo, M. P., Assfalg-Machleidt, I., Zhu-Salzman, K., Shade, R. E., An, H., Murdock, L. L., Machleidt, W., Bressan, R. A., and Hasegawa, P. M.: Phage display selection of hairpin loop soyacystatin variants that mediate high affinity inhibition of a cysteine proteinase. *Plant J.*, 27, 383-391 (2001).
25. Maun, H. R., Eigenbrot, C., and Lazarus, R. A.: Engineering exosite peptides for complete inhibition of factor VIIa using a protease switch with substrate phage. *J. Biol. Chem.*, 278, 21823-21830 (2003).
26. Kim, W. C., Rhee, H. I., Park, B. K., Suk, K. H., Cha, S. H.: Isolation of peptide ligands that inhibit glutamate racemase activity from a random phage display library. *J. Biomol. Screen.*, 5, 435-440, (2000).
27. Huang, L., Sexton, D. J., Skogerson, K., Devlin, M., Smith, R., Sanyal, I., Parry, T., Kent, R., Enright, J., Wu, Q. L., Conley, G., DeOliveira, D., Morganeli, L., Ducar, M., Wescott, C. R., and Ladner, R. C.: Novel peptide inhibitors of angiotensin-converting enzyme 2. *J. Biol. Chem.*, 278, 15532-15540 (2003).
28. Trexler, M., Briknarova, K., Gehrman, M., Llinas, M., and Patthy, L.: Peptide ligands for the fibronectin type II modules of matrix metalloproteinase 2 (MMP-2). *J. Biol. Chem.*, 278, 12241-12246 (2003).
29. Sahu, A., Kay, B. K., and Lambris, J. D.: Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. *J. Immunol.*, 157, 884-891 (1996).
30. Finlan, L. and Hupp, T. R.: The N-terminal interferon-binding domain (IBiD) homology domain of p300 binds to peptides with homology to the p53 transactivation domain. *J. Biol. Chem.*, 279, 49395-49405 (2004).
31. Huang, P. Y. and Carbonell, R. G.: Affinity chromatographic screening of soluble combinatorial peptide libraries. *Biotechnol. Bioeng.*, 63, 633-641 (1999).
32. Pierce, H. H., Adey, N., Kay, B. K.: Identification of cyclized calmodulin antagonists from a phage display random peptide library. *Mol. Divers.*, 1, 259-265 (1996).
33. Dedman, J. R., Kaetzel, M. A., Chan, H. C., Nelson, D. J., and Jamieson, G. A., Jr.: Selection of targeted biological modifiers from a bacteriophage library of random peptides. The identification of novel calmodulin regulatory peptides. *J. Biol. Chem.*, 268, 23025-23030 (1993).
34. Sato, A. K., Sexton, D. J., Morganeli, L. A., Cohen, E. H., Wu, Q. L., Conley, G. P., Streltsova, Z., Lee, S. W., Devlin, M., DeOliveira, D. B., Enright, J., Kent, R. B., Wescott, C. R., Ransohoff, T. C., Ley, A. C., and Ladner, R. C.: Development of mammalian serum albumin affinity purification media by peptide phage display. *Biotechnol. Prog.*, 18, 182-192 (2002).
35. Ramanujam, P., Tan, W. S., Nathan, S., and Yusoff, K.: Novel peptides that inhibit the propagation of Newcastle disease virus. *Arch. Virol.*, 147, 981-993 (2002).
36. Peletskaya, E. N., Glinsky, V. V., Glinsky, G. V., Deutscher, S. L., and Quinn, T. P.: Characterization of peptides that bind the tumor-associated Thomsen-Friedenreich antigen selected from bacteriophage display libraries. *J. Mol. Biol.*, 270, 374-384 (1997).
37. Bai, F. W., Zhang, H. W., Yan, J., Qu, Z. C., Xu, J., Wen, J. G., Ye, M. M., Shen, D. L.: Selection of phage-display peptides that bind specifically to the outer coat protein of rice black streaked dwarf virus. *Acta Virol.*, 46, 85-90 (2002).
38. Ho, K. L., Yusoff, K., Seow, H. F., and Tan, W. S.: Selection of high affinity ligands to hepatitis B core antigen from a phage-displayed cyclic peptide library. *J. Med. Virol.*, 69, 27-32 (2003).
39. Dybwad, A., Lambin, P., Sioud, M., and Zouali, M.: Probing the specificity of human myeloma proteins with a

- random peptide phage library. *Scand. J. Immunol.*, 57, 583-590 (2003).
40. Zhang, H. W., Qu, Z. C., Xu, X. Y., Zhang, X. N., Bai, F. W., Wan, Y. Z., Shao, M. H., Ye, M. M., and Shen, D. L.: Selection and expression of peptides which can change the conformation of p20 protein of rice stripe virus. *Acta Virol.*, 46, 11-17 (2002).
 41. Lowman, H. B., Chen, Y. M., Skelton, N. J., Mortensen, D. L., Tomlinson, E. E., Sadick, M. D., Robinson, I. C., and Clark, R. G.: Molecular mimics of insulin-like growth factor I (IGF-1) for inhibiting IGF-1: IGF-binding protein interactions. *Biochemistry*, 37, 8870-8878 (1998).
 42. Gee, S. H., Sekely, S. A., Lombardo, C., Kurakin, A., Froehner, S. C., and Kay, B. K.: Cyclic peptides as non-carboxyl-terminal ligands of syntrophin PDZ domains. *J. Biol. Chem.*, 273, 21980-21987 (1998).
 43. Skelton, N. J., Russell, S., de Sauvage, F., and Cochran, A. G.: Amino acid determinants of beta-hairpin conformation in erythropoietin receptor agonist peptides derived from a phage display library. *J. Mol. Biol.*, 316, 1111-1125 (2002).
 44. McConnell, S. J., Dinh, T., Le, M. H., Brown, S. J., Becherer, K., Blumeyer, K., Kautzer, C., Axelrod, F., and Spinella, D. G.: Isolation of erythropoietin receptor agonist peptides using evolved phage libraries. *Biol. Chem.*, 379, 1279-1286 (1998).
 45. Nakamura, G. R., Starovasnik, M. A., Reynolds, M. E., and Lowman, H. B.: A novel family of hairpin peptides that inhibit IgE activity by binding to the high-affinity IgE receptor. *Biochemistry*, 40, 9828-9835 (2001).
 46. Houimel, M., Schneider, P., Terskikh, A., and Mach, J. P.: Selection of peptides and synthesis of pentameric peptabody molecules reacting specifically with ErbB-2 receptor. *Int. J. Cancer*, 92, 748-755 (2001).
 47. Nakamura, G. R., Reynolds, M. E., Chen, Y. M., Starovasnik, M. A., and Lowman, H. B.: Stable "zeta" peptides that act as potent antagonists of the high-affinity IgE receptor. *Proc. Natl. Acad. Sci. USA*, 99, 1303-1308 (2002).
 48. Hessling, J., Lohse, M. J., and Klotz, K. N.: Peptide G protein agonists from a phage display library. *Biochem. Pharmacol.*, 65, 961-967 (2003).
 49. Wrighton, N. C., Farrell, F. X., Chang, R., Kashyap, A. K., Barbone, F. P., Mulcahy, L. S., Johnson, D. L., Barrett, R. W., Jolliffe, L. K., Dower, W. J.: Small peptides as potent mimetics of the protein hormone erythropoietin. *Science*, 273, 458-464 (1996).
 50. Livnah, Om, Stura, E. A., Johnson, D. L., Middleton, S. A., Mulcahy, L. S., Wrighton, N. C., Dower, W. J., Jolliffe, L. K., and Wilson, I. A.: Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 Å. *Science*, 273, 464-471 (1996).
 51. El-Mousawi, M., Tchistiakova, L., Yurchenko, L., Pietrzynski, G., Moreno, M., Stanimirovic, D., Ahmad, D., and Alakhov, V.: A vascular endothelial growth factor high affinity receptor 1-specific peptide with antiangiogenic activity identified using a phage display peptide library. *J. Biol. Chem.*, 278, 46681-46691 (2003).
 52. Wang, B.S. and Pabo, C.O.: Dimerization of zinc fingers mediated by peptides evolved in vitro from random sequences. *Proc. Natl. Acad. Sci. USA*, 96, 9568-9573 (1999).
 53. Lee, L., Buckley, C., Blades, M. C., Panayi, G., George, A. J., and Pitzalis, C.: Identification of synovium-specific homing peptides by in vivo phage display selection. *Arthritis Rheum.*, 46, 2109-2120 (2002).
 54. Kennel, S. J., Mirzadeh, S., Hurst, G. B., Foote, L. J., Lankford, T. K., Glowienka, K. A., Chappell, L. L., Kelso, J. R., Davern, S. M., Safavy, A., and Brechbiel, M. W.: Labeling and distribution of linear peptides identified using in vivo phage display selection for tumors. *Nucl. Med. Biol.*, 27, 815-825 (2000).
 55. Essler, M. and Ruoslahti, E.: Molecular specialization of breast vasculature: a breast-homing phage-displayed peptide binds to aminopeptidase P in breast vasculature. *Proc. Natl. Acad. Sci. USA*, 99, 2252-2257 (2002).
 56. Spear, M. A., Breakefield, X. O., Beltzer, J., Schuback, D., Weissleder, R., Pardo, F. S., and Ladner, R.: Isolation, characterization, and recovery of small peptide phage display epitopes selected against viable malignant glioma cells. *Cancer Gene Ther.*, 8, 506-511 (2001).
 57. Curiel, T. J., Morris, C., Brumlik, M., Landry, S. J., Finstad, K., Nelson, A., Joshi, V., Hawkins, C., Alarez, X., Lackner, A., and Mohamadzadeh, M.: Peptides identified through phage display direct immunogenic antigen to dendritic cells. *J. Immunol.*, 172, 7425-7431 (2004).
 58. Gao, C., Mao, S., Ditzel, H. J., Farnaes, L., Wirsching, P., Lerner, R. A., and Janda, K. D.: A cell-penetrating peptide from a novel pVII-pIX phage-displayed random peptide library. *Bioorg. Med. Chem.*, 10, 4057-4065 (2002).
 59. Eidne, K. A., Henery, C. C., and Aitken, R. J.: Selection of peptides targeting the human sperm surface using random peptide phage display identify ligands homologous to ZP3. *Biol. Reprod.* 63, 1396-1402 (2000).
 60. Tinoco, L. W., Da Silva, A., Jr., Leite, A., Valente, A. P., and Almeida, F. C.: NMR structure of PW2 bound to SDS micelles. A tryptophan-rich anticoccidial peptide selected from phage display libraries. *J. Biol. Chem.*, 277, 36351-36356 (2002).
 61. Ardelt, P. U., Wood, C. G., Chen, L., Mintz, P. J., Moya, C., Arap, M. A., Wright, K. C., Pasqualini, R., and Arap, W.: Targeting urothelium: ex vivo assay standardization and selection of internalizing ligands. *J. Urol.*, 169, 1535-1540 (2003).
 62. Rasmussen, U. B., Schreiber, V., Schultz, H., Mischler, F., and Schughart, K.: Tumor cell-targeting by phage-displayed peptides. *Cancer Gene Ther.*, 9, 606-612 (2002).
 63. Samoylova, T. I., Ahmed, B. Y., Vodyanov, V., Morrison, N. E., Samoylov, A. M., Globa, L. P., Baker, H. J., and Cox, N. R.: Targeting peptides for microglia identified via phage display. *J. Neuroimmunol.*, 127, 13-21 (2002).

64. Smith, G. P. and Petrenko, V.A.: Phage display. *Chem. Rev.*, 97, 391-410 (1997).
65. Cortese, R., Monaci, P., Nicosia, A., Luzzago, A., Felici, F., Galfre, G., Pessi, A., Tramontano, A., and Sollazzo, M.: Identification of biologically active peptides using random libraries displayed on phage. *Curr. Opin. Biotechnol.*, 6, 73-80 (1995).
66. Burritt, J. B., Bond, C. W., Doss, K. W., and Jesaitis, A. J.: Filamentous phage display of oligopeptide libraries. *Anal. Biochem.*, 238, 1-13 (1996).
67. McLafferty, M. A., Kent, R. B., Ladner, R. C., and Markland, W.: M13 bacteriophage displaying disulfide-constrained microproteins. *Gene*, 128, 29-36 (1993).
68. Ladner, R. C.: Constrained peptides as binding entities. *Trends Biotechnol.* 13, 426-430 (1995).
69. Ladner, R. C., Sato, A. K., Gorzelany, J., and de Souza, M.: Phage display-derived peptides as therapeutic alternatives to antibodies. *Drug Discov Today*, 9, 525-529 (2004).
70. Wang, L. F. and Yu, M.: Epitope identification and discovery using phage display libraries: applications in vaccine development and diagnostics. *Curr. Drug Targets*, 5, 1-15 (2004).
71. Edwards, M. R., Collins, A. M., and Ward, R. L.: The application of phage display in allergy research: characterization of IgE, identification of allergens and development of novel therapeutics. *Curr. Pharm. Biotechnol.*, 2, 225-240 (2001).
72. Nakashima, T., Ishiguro, N., Yamaguchi, M., Yamauchi, A., Shima, Y., Nozaki, C., Urabe, I., and Yomo, T.: Construction and characterization of phage libraries displaying artificial proteins with random sequences. *J. Biosci. Bioeng.*, 90, 253-259 (2000).
73. Zhuang, G., Katakura, Y., Furuta, T., Omasa, T., Kishimoto, M., and Suga, K.: A kinetic model for a biopanning process considering antigen desorption and effective antigen concentration on a solid phase. *J. Biosci. Bioeng.*, 91, 474-481 (2001).
74. Petit, M. A., Jolivet-Reynaud, C., Peronnet, E., Michal, Y., and Trepo, C.: Mapping of a conformational epitope shared between E1 and E2 on the serum-derived human hepatitis C virus envelope. *J. Biol. Chem.*, 278, 44385-44392 (2003).
75. Leinonen, J., Wu, P., and Stenman, U. H.: Epitope mapping of antibodies against prostate-specific antigen with use of peptide libraries. *Clin. Chem.*, 48, 2208-2216 (2002).
76. Coley, A. M., Campanale, N. V., Casey, J. L., Hodder, A. N., Crewther, P. E., Anders, R. F., Tilley, L. M., and Foley, M.: Rapid and precise epitope mapping of monoclonal antibodies against *Plasmodium falciparum* AMA1 by combined phage display of fragments and random peptides. *Protein Eng.*, 14, 691-698 (2001).
77. Myers, M. A., Davies, J. M., Tong, J. C., Whisstock, J., Scealy, M., Mackay, I.R., and Rowley, M. J.: Conformational epitopes on the diabetes autoantigen GAD65 identified by peptide phage display and molecular modeling. *J. Immunol.*, 165, 3830-3838 (2000).
78. Rowley, M. J., Scealy, M., Whisstock, J. C., Jois, J. A., Wijeyewickrema, L. C., and Mackay, I. R.: Prediction of the immunodominant epitope of the pyruvate dehydrogenase complex E2 in primary biliary cirrhosis using phage display. *J. Immunol.*, 164, 3413-3419 (2000).
79. Pincus, S. H., Smith, M. J., Jennings, H. J., Burritt, J. B., and Glee, P. M.: Peptides that mimic the group B streptococcal type III capsular polysaccharide antigen. *J. Immunol.*, 160, 293-298 (1998).
80. Valadon, P., Nussbaum, G., Boyd, L. F., Margulies, D. H., and Scharff, M. D.: Peptide libraries define the fine specificity of anti-polysaccharide antibodies to *Cryptococcus neoformans*. *J. Mol. Biol.*, 261, 11-22 (1996).
81. Hou, Y. and Gu, X. X.: Development of peptide mimotopes of lipooligosaccharide from nontypeable *Haemophilus influenzae* as vaccine candidates. *J. Immunol.*, 170, 4373-4379 (2003).
82. Stephen, C. W., Helminen, P., and Lane, D.P.: Characterisation of epitopes on human p53 using phage-displayed peptide libraries: insights into antibody-peptide interactions. *J. Mol. Biol.*, 248, 58-78 (1995).
83. Kay, B. K., Adey, N. B., He, Y. S., Manfredi, J. P., Mataragnon, A. H., and Fowlkes, D. M.: An M13 phage library displaying random 38-amino-acid peptides as a source of novel sequences with affinity to selected targets. *Gene*, 128, 59-65 (1993).
84. Giebel, L. B., Cass, R. T., Milligan, D. L., Young, D. C., Arze, R., and Johnson, C. R.: Screening of cyclic peptide phage libraries identifies ligands that bind streptavidin with high affinities. *Biochemistry*, 34, 15430-15435 (1995).
85. Weber, P. C., Pantoliano, M.W., and Thompson, L. D.: Crystal structure and ligand-binding studies of a screened peptide complexed with streptavidin. *Biochemistry*, 31, 9350-9354 (1992).
86. Katz, B. A.: Binding to protein targets of peptidic leads discovered by phage display: crystal structures of streptavidin-bound linear and cyclic peptide ligands containing the HPQ sequence. *Biochemistry*, 34, 15421-15429 (1995).
87. Skelton, N. J., Chen, Y. M., Dubree, N., Quan, C., Jackson, D. Y., Cochran, A., Zobel, K., Deshayes, K., Baca, M., Pisabarro, M. T., and Lowman, H. B.: Structure-function analysis of a phage display-derived peptide that binds to insulin-like growth factor binding protein 1. *Biochemistry*, 40, 8487-8498 (2001).
88. Nunez Miguel, R., Sanders, J., Jeffrey, J., Depraetere, H., Evans, M., Richards, T., Blundell, T. L., Rees Smith, B., and Furmaniak, J.: Analysis of the thyrotropin receptor-thyrotropin interaction by comparative modeling. *Thyroid*, 14, 991-1011 (2004).
89. Onoue, S., Matsumoto, A., Nagano, Y., Ohshima, K., Ohmori, Y., Yamada, S., Kimura, R., Yajima, T., and

- Kashimoto, K.: Alpha-helical structure in the C-terminus of vasoactive intestinal peptide: functional and structural consequences. *Eur. J. Pharmacol.*, 485, 307-16 (2004).
90. Petrenko, V. A., Smith, G. P., Mazooji, M. M., and Quinn, T.: Alpha-helically constrained phage display library. *Protein Eng.*, 15, 943-950, (2002).
 91. Fujii, I., Takaoka, Y., Suzuki, K., and Tanaka, T.: A conformationally purified α -helical peptide library. *Tetrahedron Lett.*, 42, 3323-3325 (2001).
 92. Rodi, D. J., Soares, A. S. and Makowski, L.: Quantitative assessment of peptide sequence diversity in M13 combinatorial peptide phage display libraries. *J. Mol. Biol.* 322, 1039-1052 (2002).
 93. Brazeau, P., Vale, W., Burgus, R., Ling, N., Butcher, M., Rivier, J., and Guillemin, R.: Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. *Science*, 179, 77-79 (1973).
 94. Reisine, T. and Bell, G. I.: Molecular biology of somatostatin receptors. *Endocr. Rev.*, 16, 427-442 (1995).
 95. Hirschmann, R., Nicolaou, K. C., Pietranico, S., Leahy, E. M., Salvino, J., Arison, B., Cichy, M. A., Grant Spoor, P., Shakespeare, W. C., Sprengeler, P. A., and other 10 authors: De Novo design and synthesis of somatostatin non-peptide peptidomimetics utilizing beta-D-glucose as a novel scaffolding. *J. Am. Chem. Soc.*, 115, 12550-12568 (1993)
 96. Damour, D., Barreau, M., Blanchard, J-C., Burgevin, M-C., Doble, A., Herman, F., Pantel, G., James-Surcouf, E., Vuilhorgne, M., Mignani, S., Poitout, L., Le Merrer, Y., and Depey, J-C.: Design, synthesis and binding affinities of novel non-peptide mimics of somatostatin/sandostatin. *Bioorg. Med. Chem. Lett.*, 6, 1667-1672 (1996).
 97. Cheng, R. P., Suich, D. J., Cheng, H., Roder, H., and DeGrado, W. F.: Template-constrained somatostatin analogues: a biphenyl linker induces a type-V' turn. *J. Am. Chem. Soc.*, 123, 12710-12711 (2001).
 98. Yang, L., Berk, S. C., Rohrer, S. P., Mosley, R. T., Guo, L., Underwood, D. J., Arison, B. H., Birzin, E. T., Hayes, E. C., Mitra, S. W., and other 13 authors: Synthesis and biological activities of potent peptidomimetics selective for somatostatin receptor subtype 2. *Proc. Natl. Acad. Sci. USA*, 95, 10836-10841 (1998).
 99. Ankersen, M., Crider, M., Liu, S., Ho, B., Anderson, H. S., and Stidsen, C.: Discovery of a novel non-peptide somatostatin agonist with SST4 selectivity. *J. Am. Chem. Soc.*, 120, 1368-1373 (1998).
 100. Rose, G D., Gierasch, L. M., and Smith, J. A.: Turns in peptides and proteins. *Adv. Protein Chem.*, 37, 1-97 (1985)
 101. Nagi, A. D. and Regan, L.: An inverse correlation between loop length and stability in a four-helix-bundle protein. *Fold. Des.*, 2, 67-75 (1997).
 102. Li, B., Tom, J. Y., Oare, D., Yen, R., Fairbrother, W. J., Wells, J. A., and Cunningham, B. C.: Minimization of a polypeptide hormone. *Science*, 270, 1657-1660 (1995).
 103. Sidhu, S. S., Lowman, H. B., Cunningham, B. C., and Wells, J. A.: Phage display for selection of novel binding peptides. *Methods Enzymol.*, 328, 333-363 (2000).
 104. Pflugrath, J. W., Wiegand, G., Huber, R., and Vertesy, L.: Crystal structure determination, refinement and the molecular model of the alpha-amylase inhibitor Hoe-467A. *J. Mol. Biol.*, 189, 383-386 (1986).
 105. Takahashi, M., Nokihara, K., and Mihara, H.: Construction of a protein-detection system using a loop peptide library with a fluorescence label. *Chem. Biol.*, 10, 53-60 (2003).
 106. McConnell, S. J. and Hoess, R. H.: Tendamistat as a scaffold for conformationally constrained phage peptide libraries. *J. Mol. Biol.*, 250, 460-470 (1995).
 107. Li, R., Hoess, R. H., Bennett, J. S., and DeGrado, W. F.: Use of phage display to probe the evolution of binding specificity and affinity in integrins. *Protein Eng.*, 16, 65-72 (2003).
 108. Liu, J., Underwood, D. J., Cascieri, M. A., Rohrer, S. P., Cantin, L. D., Chicchi, G., Smith, A. B., 3rd, and Hirschmann, R.: Synthesis of a substance P antagonist with a somatostatin scaffold: factors affecting agonism/antagonism at GPCRs and the role of pseudosymmetry. *J. Med. Chem.*, 43, 3827-3831 (2000).
 109. Janin, J. and Chothia, C.: The structure of protein-protein recognition sites. *J. Biol. Chem.*, 265, 16027-16030 (1990).
 110. Clackson, T. and Wells, J. A.: A hot spot of binding energy in a hormone-receptor interface. *Science*, 267, 383-386 (1995).
 111. Hsu, C. L., Chen, Y. L., Yeh, S., Ting, H. J., Hu, Y. C., Lin, H., Wang, X., and Chang, C.: The use of phage display technique for the isolation of androgen receptor interacting peptides with (F/W)XXL(F/W) and FXXLY new signature motifs. *J. Biol. Chem.*, 278, 23691-23698 (2003).
 112. Stefanidakis, M., Bjorklund, M., Ihanus, E., Gahmberg, C. G., and Koivunen, E.: Identification of a negatively charged peptide motif within the catalytic domain of progelatinases that mediates binding to leukocyte beta 2 integrins. *J. Biol. Chem.*, 278, 34674-34784 (2003).
 113. Liang, O. D., Chavakis, T., Linder, M., Bdeir, K., Kuo, A., and Preissner, K. T.: Binding of urokinase plasminogen activator to gp130 via a putative urokinase-binding consensus sequence. *Biol. Chem.*, 384, 229-236 (2003).
 114. Su, Y., Zhou, A., Al-Lamki, R. S., and Karet, F. E.: The α -subunit of the V-type H⁺-ATPase interacts with phosphofructokinase-1 in humans. *J. Biol. Chem.*, 278, 20013-20018 (2003).
 115. Mintz, P. J., Kim, J., Do, K. A., Wang, X., Zinner, R. G., Cristofanilli, M., Arap, M. A., Hong, W. K., Troncoso, P., Logothetis, C. J., Pasqualini, R., and Arap, W.: Fingerprinting the circulating repertoire of antibodies from cancer patients. *Nat. Biotechnol.*, 21, 37-38 (2003).
 116. Molenaar, T. J., Appeldoorn, C. C., de Haas, S. A., Michon, I. N., Bonnefoy, A., Hoylaerts, M. F., Pannekoek, H., van Berkel, T. J., Kuiper, J., and Biessen, E. A.: Specific inhibition of P-selectin-mediated cell adhesion by

- phage display-derived peptide antagonists. *Blood*, 100, 3570-3577 (2002).
117. Gazouli, M., Han, Z., and Papadopoulos, V.: Identification of a peptide antagonist to the peripheral-type benzodiazepine receptor that inhibits hormone-stimulated leydig cell steroid formation. *J. Pharmacol. Exp. Ther.*, 303, 627-632 (2002).
118. Maruta, F., Parker, A. L., Fisher, K. D., Hallissey, M. T., Ismail, T., Rowlands, D. C., Chandler, L. A., Kerr, D. J., and Seymour, L. W.: Identification of FGF receptor-binding peptides for cancer gene therapy. *Cancer Gene Ther.*, 9, 543-552 (2002).
119. Koivunen, E., Ranta, T. M., Annala, A., Taube, S., Uppala, A., Jokinen, M., van Willigen, G., Ihanus, E., and Gahmberg, C. G.: Inhibition of beta(2) integrin-mediated leukocyte cell adhesion by leucine-leucine-glycine motif-containing peptides. *J. Cell Biol.*, 153, 905-916 (2001).
120. Tamm, I., Trepel, M., Cardo-Vila, M., Sun, Y., Welsh, K., Cabezas, E., Swatterthwait, A., Arap, W., Reed, J. C., and Pasqualini, R.: Peptides targeting caspase inhibitors. *J. Biol. Chem.*, 278, 14401-14405 (2003).